• Je něco špatně v tomto záznamu ?

Enzybiotics LYSSTAPH-S and LYSDERM-S as Potential Therapeutic Agents for Chronic MRSA Wound Infections

L. Vacek, Š. Kobzová, R. Čmelík, R. Pantůček, L. Janda,

. 2020 ; 9 (8) : . [pub] 20200815

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021806

Grantová podpora
NV19-05-00214 Agency for Health Research of the Czech Republic

Antibacterial antibiotic therapy has played an important role in the treatment of bacterial infections for almost a century. The increasing resistance of pathogenic bacteria to antibiotics leads to an attempt to use previously neglected antibacterial therapies. Here we provide information on the two recombinantly modified antistaphylococcal enzymes derived from lysostaphin (LYSSTAPH-S) and endolysin (LYSDERM-S) derived from kayvirus 812F1 whose target sites reside in the bacterial cell wall. LYSSTAPH-S showed a stable antimicrobial effect over 24-h testing, even in concentrations lower than 1 µg/mL across a wide variety of epidemiologically important sequence types (STs) of methicillin-resistant Staphylococcus aureus (MRSA), especially in the stationary phase of growth (status comparable to chronic infections). LYSDERM-S showed a less potent antimicrobial effect that lasted only a few hours at concentrations of 15 μg/mL and higher. Our data indicate that these antimicrobial enzymes could be of substantial help in the treatment of chronic MRSA wound infections.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021806
003      
CZ-PrNML
005      
20201204092756.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics9080519 $2 doi
035    __
$a (PubMed)32824115
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vacek, Lukáš $u Clinical Immunology and Immunology of Infectious Diseases, Veterinary Research Institute, Brno, Hudcova 70, 62100 Brno, Czech Republic. Department of Microbiology, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Pekařská 53, 65691 Brno, Czech Republic.
245    10
$a Enzybiotics LYSSTAPH-S and LYSDERM-S as Potential Therapeutic Agents for Chronic MRSA Wound Infections / $c L. Vacek, Š. Kobzová, R. Čmelík, R. Pantůček, L. Janda,
520    9_
$a Antibacterial antibiotic therapy has played an important role in the treatment of bacterial infections for almost a century. The increasing resistance of pathogenic bacteria to antibiotics leads to an attempt to use previously neglected antibacterial therapies. Here we provide information on the two recombinantly modified antistaphylococcal enzymes derived from lysostaphin (LYSSTAPH-S) and endolysin (LYSDERM-S) derived from kayvirus 812F1 whose target sites reside in the bacterial cell wall. LYSSTAPH-S showed a stable antimicrobial effect over 24-h testing, even in concentrations lower than 1 µg/mL across a wide variety of epidemiologically important sequence types (STs) of methicillin-resistant Staphylococcus aureus (MRSA), especially in the stationary phase of growth (status comparable to chronic infections). LYSDERM-S showed a less potent antimicrobial effect that lasted only a few hours at concentrations of 15 μg/mL and higher. Our data indicate that these antimicrobial enzymes could be of substantial help in the treatment of chronic MRSA wound infections.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kobzová, Šárka $u Clinical Immunology and Immunology of Infectious Diseases, Veterinary Research Institute, Brno, Hudcova 70, 62100 Brno, Czech Republic.
700    1_
$a Čmelík, Richard $u Institute of Analytical Chemistry of the Czech Academy of Sciences, Veveří 97, 60200 Brno, Czech Republic.
700    1_
$a Pantůček, Roman $u Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic.
700    1_
$a Janda, Lubomír $u Clinical Immunology and Immunology of Infectious Diseases, Veterinary Research Institute, Brno, Hudcova 70, 62100 Brno, Czech Republic.
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 9, č. 8 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32824115 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204092754 $b ABA008
999    __
$a ind $b bmc $g 1591515 $s 1112478
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 8 $e 20200815 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
GRA    __
$a NV19-05-00214 $p Agency for Health Research of the Czech Republic
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace